At a glance
ClinicalIndex Comparison Record- ✓Recurrent, progressing, and/or refractory solid tumors with completion or ineligibility for standard of care
- ✓ECOG performance status 0-1
- ✓HLA-A*02:01 positive
- ✓Confirmed high-grade serous or endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (ovarian/fallopian tube patients only)
- ✕History of other malignancies within last 3 years (except basal/squamous cell carcinoma or carcinoma in situ)
- ✕Pregnant or breastfeeding
- ✕Serious autoimmune disease (may be included if well controlled without immunosuppressive agents at investigator discretion)
- ✕History of cardiac conditions per protocol
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
In Brief
A Phase 2 clinical trial evaluating IMA203 Product, IMA203 product- flat dose, and 3 other interventions for Refractory Cancer and 3 related conditions. Currently recruiting, targeting 375 participants across 21 sites in 2 countries.
Signals
Detailed Summary
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Study Details
Timeline
Interventions
The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells
The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.
IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.